Cushman W.C.
472
Coauthors
10
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Medicina interna | 9 |
| Diabetes | 8 |
| Medicamento | 3 |
| Enfermedad cardiovascular | 1 |
| Cognición | 1 |
| Neurología | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 9 |
| Farmacología y terapéutica | 9 |
| Medicina y salud | 4 |
| Fisiología humana | 3 |
| Ginecología, obstetricia, pediatría, geriatría | 1 |
| Medicina forense; incidencia de enfermedades | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 10 |
| Google Scholar | 8 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Leiter L.A. | 9 |
| Pogosova N. | 9 |
| PATRICIO LOPEZ -JARAMILLO | 9 |
| Sheu W.H.H. | 9 |
| Rydén L.E. | 9 |
| Basile J.N. | 9 |
| Raubenheimer P.J. | 9 |
| Probstfield J.L. | 9 |
| Colhoun H.M. | 8 |
| Gerstein H.C. | 8 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
ArticleAbstract: Aim: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) inPalabras claves:Atrial Fibrillation, atrial flutter, dulaglutide, glucagon-like peptide-1 receptor agonists, Type 2 DiabetesAutores:Avezum A.J., Basile J.N., C. Gerstein H., Conget I., Cushman W.C., Dagenais G.R., Hoover A., Jansky P., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusErectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial
ArticleAbstract: Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 rPalabras claves:Autores:Bajaj H.S., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Franek E., Gerstein H.C., Hanefeld M., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Shaw J.E., Sheu W.H.H., Xavier D.Fuentes:googlescopusSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
ArticleAbstract: Objective : Recent European Guidelines for Diabetes, Pbkp_rediabetes and Cardiovascular Diseases intPalabras claves:Cardiovascular disease, GLP-1-based therapy, Metformin, Morbidity, MortalityAutores:Avezum A.J., Basile J.N., Colhoun H.M., Cushman W.C., Dagenais G.R., DIaz R., Dyal L., Ferrannini G., Gerstein H.C., Jansky P., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Mellbin L., Pais P., PATRICIO LOPEZ -JARAMILLO, PīrCrossed D Sign gs V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H.Fuentes:googlescopusTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
ArticleAbstract: Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) doublePalabras claves:Cardiovascular disease, Glucagon like peptide-1 receptor agonists, Type 2 DiabetesAutores:Atisso C.M., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Dyal L., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusEffect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
ArticleAbstract: Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigatePalabras claves:Autores:Atisso C.M., Basile J.N., Bethel A., Colhoun H.M., Cukierman-Yaffee T., Cushman W.C., DIaz R., Franek E., García-Pérez L.E., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:googlescopus